• Frédéric-Antoine Dauchy, Sylvie Lawson-Ayayi, Renaud de La Faille, Fabrice Bonnet, Claire Rigothier, Nadia Mehsen, Ghada Miremont-Salamé, Charles Cazanave, Carine Greib, Francois Dabis, and Michel Dupon.
• Services de Maladies Infectieuses et Tropicales and COREVIH, Hôpital Pellegrin, CHU de Bordeaux, Université Bordeaux Segalen, Bordeaux, France. frederic.dauchy@chu-bordeaux.fr
• Kidney Int. 2011 Aug 1;80(3):302-9.

AbstractAbnormal kidney function is common in the course of human immunodeficiency virus (HIV) infection. Here, we performed a cross-sectional analysis using 399 patients within the Aquitaine cohort (a hospital-based cohort of HIV-1-infected patients receiving routine clinical management) to estimate the prevalence of proximal renal tubular dysfunction (PRTD) associated with HIV infection. These patients did not differ statistically by sociodemographics, median age, years since HIV diagnosis, AIDS stage, or median CD4 cell count from the entire 3080 patient cohort. Antiretroviral therapy was received by 352 patients, with 256 given tenofovir (TDF); 325 had undetectable HIV plasma viral load, and 26 were diagnosed with PRTD. In multivariate analysis, significant independent associations were found between PRTD and age (odds ratio (OR) 1.28 per 5-year increase), atazanavir (OR 1.28 per year of exposure), and TDF (OR 1.23 per year) treatment. Among patients having received TDF-containing regimens over a 5-year period, PRTD remained significantly associated with TDF exposure when treatment was ongoing (OR 5.22) or had been discontinued (OR 11.49). Thus, cumulative exposure to TDF and/or atazanavir was associated with an increased risk of PRTD, with concern about its reversibility in patients with HIV.

44 keywords...

hide…